Perioperative chemotherapy in gastroesophageal cancer. A retrospective monocenter evaluation of 42 cases.

摘要: Background Perioperative chemotherapy increases the overall and progression-free survival of patients suffering from resectable adenocarcinomas lower esophagus, gastroesophageal junction stomach (GEC). Comparing different regimens platin-based protocols with 5-fluorouracil (5-FU)/calcium folinate (CF) or oral fluoropyrimidines were favorable in terms efficacy side-effects. However, there is no consensus which regimen most efficacious. Methods 42 consecutive GEC (UICC II III) treated 3 pre- postoperative cycles each consisting epirubicin, oxaliplatin capecitabine (EOX). We analyzed survival, toxicity retrospectively comparison to published data. Results The median our cohort was 29 months 17 months. The frequent grade 4 toxicities during preoperative diarrhea (16.7%), leukocytopenia (9.5%) nausea (9.5%); 38.1% suffered toxicity. Surgery carried out 83% patients, 69% those achieved R0 resection. Conclusion Comparing data results previously randomized trials EOX at least non-inferior regard In conclusion, an appropriate perioperative therapy for GEC.